Bruce Car's departure as Chief Scientific Officer of Biohaven Ltd. was reported, effective July 13, 2026; the filing names no successor. As of November 6, 2026, Biohaven Ltd. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 9, 2026 to August 7, 2026, naming 2 appointments and 1 departure (Form 8-K, July 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Biohaven Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Biohaven Ltd. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-09 to 2026-08-07. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Biohaven Ltd. files it.
Also on the record for Biohaven Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Woodline Partners LP | 5.1% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 5.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 11.7% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by SUVRETTA CAPITAL MANAGEMENT, LLC | 7.8% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 12.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 6.4% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 2.71% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 4.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Biohaven Ltd. now and the warning signs.
Free to see. No signup.
Keep reading
More on Biohaven Ltd. and the records around it.
Biohaven Ltd. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026), CervoMed Inc. (Aug 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Biohaven Ltd.
Get an email when Biohaven Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biohaven Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Biohaven Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biohaven Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-07 | In | Director | 2026-08-06 | 8-K, 2026-08-07 | |
| 2026-07-09 | Out | Chief Scientific Officer | 2026-07-13 | 8-K, 2026-07-09 | |
| 2026-07-09 | In | Executive Vice President | 2026-07-13 | 8-K, 2026-07-09 |
Who leads Biohaven Ltd., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John Yetimoglu, appointed, effective 2026-08-06 (filed 2026-08-07).
- Executive Vice President: David Pirman, appointed, effective 2026-07-13 (filed 2026-07-09).
- Chief Scientific Officer: Bruce Car, departure reported, effective 2026-07-13 (filed 2026-07-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Biohaven Ltd.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Biohaven Ltd., with the record behind each one.
Find candidates like Director at Biohaven Ltd.Every change, in the filing's words
Appointed: John Yetimoglu, Director, effective 2026-08-06
On August 3, 2026, the Board of Directors (the "Board") of Biohaven Ltd. (the "Company") appointed John Yetimoglu as a director, effective August 6, 2026.
- Mr. Yetimoglu will serve in the class of directors whose term will expire at the Company's 2027 Annual Meeting of Shareholders.
- Mr. Yetimoglu has also been appointed as a member of the Nominating and Governance Committee of the Board.
- The shares underlying these options will vest 25% on grant and 25% on each of the following three anniversaries of grant, subject to Mr. Yetimoglu's continuous service through each vesting date.
Departing: Bruce Car, Chief Scientific Officer, effective 2026-07-13
On July 9, 2026, Biohaven Ltd. (the "Company") and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer.
Appointed: David Pirman, Executive Vice President, effective 2026-07-13
In connection with this transition, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, effective July 13, 2026.
- As Chief Innovation Officer, Dr. Car will focus on advancing Biohaven's scientific initiatives and external collaborations, including leading multiple assets under the Company's collaboration with Bexorg, Inc. Dr. Car will continue to serve as an executive officer of the Company.
- In this role, Dr. Pirman will lead the Company's internal drug-discovery organization, overseeing research programs.
- In connection with his transition to a part-time role, Dr. Car's salary will be reduced by fifty percent (50%) to reflect his work schedule.
Tools for this story
Each opens in a new tab, filled in for Biohaven Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.